A study of the effect of BIIB122/DNL151 on midazolam in healthy participants

Phase 1

Completed

• Conditions: Healthy volunteers; Not Applicable

• Registration Number: ISRCTN77591825
• Lead Sponsor: Denali Therapeutics Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-11-19
• Study Start: 2024-04-15
• Last Update Posted: 21 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Healthy female participants of non-childbearing potential or healthy male participants between 18 and 50 years of age, inclusive
2. Body mass index (BMI) between 18.5 and 31.0 kg/m² and a body weight of at least 50 kg

Exclusion Criteria

1. Take any concomitant medication at the time of screening or during the study, unless deemed acceptable by the investigator (or designee) and Sponsor
2. Any history of hepatic, pulmonary, and/or renal disease
3. History of serious adverse reaction or serious hypersensitivity to any drug
4. History of allergy to any component of the study intervention
5. Have any surgical or medical condition affecting drug absorption (eg, gastrectomy)

Study & Design

• Study Type: Interventional
• Study Design: Not specified